EQPT heads into its Q2 earnings report today with a borrow market that has shifted dramatically in bulls' favour over the past three weeks.
The clearest signal is in how sharply the lending squeeze has eased. Through most of July, availability was essentially exhausted — dropping below 2% for nearly two consecutive weeks as every available share in the lending pool was lent out, with cost to borrow touching 4–5%. That pressure has since unwound materially. Availability has recovered to roughly 62%, and the borrow rate has fallen back to around 1.95% — still up 73% week-on-week as short sellers re-enter, but far removed from the acute squeeze conditions of mid-July. Short interest itself jumped 18.5% in a single session on August 11, reaching approximately 17 million shares per ORTEX's daily estimate, though it remains well below the late-July peak of around 23.7 million shares. The ORTEX short score sits elevated at 74.7, near a one-week high, suggesting the model still reads the positioning as meaningfully bearish. Options, by contrast, offer no alarm: the put/call ratio of 0.15 is only modestly above its 20-day average of 0.13, and call-side activity has dominated for weeks — options traders are not hedging aggressively into this print.
The bull and bear cases on EQPT are genuinely divergent, and recent analyst moves reflect that tension. Wells Fargo cut its target from $32 to $25 in mid-July while holding its Overweight rating — a signal of conviction tempered by near-term concern. Citigroup, maintaining a Neutral stance, nudged its target up to $19 after a series of reductions, leaving it well below the current $20.68 price. The consensus mean of $34.50 is more generous, anchored by Truist's Buy rating and a $38 target and Citizens' Market Outperform with a $42 target. Bulls point to co-founder insider buying in June — two separate purchases totalling around $2.1 million at prices between $20.83 and $21.50 — and first-quarter results that beat guidance, with full-year 2026 guidance raised. Bears counter with concentration risk: the OWN Program accounts for 56% of total original equipment cost, and fleet age of approximately 30 months raises questions about capital requirements ahead. The stock is up 11% over the past month to $20.68, recovering sharply from lows, yet still roughly 18% below where it started the year.
The co-founder buying cluster deserves particular attention. William and Jabbok Schlacks each purchased 50,000 shares and 50,000 shares respectively in June, with each holding nearly 7.5% of the company. A board director added shares in May, and the CFO bought in January. Net insider purchases over the trailing 90 days total approximately 131,800 shares worth $2.9 million — a concentrated signal from people who built the business. The top institutional register is also notable: Romulus Capital holds nearly 22% and Anchorage Capital holds just over 7%, alongside newer entrants T. Rowe Price and Wellington Management, both of which established fresh positions as recently as June 30.
Today's print will test whether EquipmentShare's raised full-year guidance and technology-platform narrative can be reconciled with the margin profile bears argue the OWN Program concentration and fleet replacement cycle make increasingly difficult to sustain.
See the live data behind this article on ORTEX.
Open EQPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
